Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3257-3261

  Mattioli, R ^a   Lippe, Paolo ^a,f   Massacesi, C ^d   Cappelletti, C ^a   Nacciarriti, D ^b   Bisonni, R ^b   Graziano, F ^c   Menichetti, E T ^b   Imperatori, L ^a   Testa, E ^c   Laici, G ^a   Balletta, A ^e   Silva, R R ^b  

^a Medical Oncology Units   (Italy)

^b Cardiology Unit ^*  (Italy)

^c Oncology Unit   (Italy)

^d Oncol/Radiother Dept of Ancona   (Italy)

^e Cardiology Unit   (Italy)

^f S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Docetaxel; Doxorubicin; Metastatic breast cancer

Indexed keywords

DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EDEMA; EYE IRRITATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HORMONAL THERAPY; HUMAN; INFECTION; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; TAXOIDS;

EID: 6344280155     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Honig SF: Treatment of metastatic disease: Hormonal and chemotherapy. In: Harris JR, Lippman ME, Morrow M et al: (eds): Diseases of the Breast. Lippincott-Raven, Philadelphia, PA, 1996, pp 669-734.
2. A'Hern RPA, Smith IE and Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801-805, 1993.
3. Bissery MC, Nohynek G, Sandernink GJ et al: Docetaxel: A review of preclinical and clinical experience-Part I. Clinical experience. Anti-Cancer Drugs 6: 1943-1951, 1995.
4. Rowinsky EK and Donehower RC: Drug therapy: Paclitaxel. N Eng J Med 332: 1004-1014, 1995.
5. Sledge GW, Neuberg D, Bernardo P et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003.
6. Paridaens R, Biganzoli L, Bruning P et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724, 2000.
7. Chan S, Friedrichs K, Noel D et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341, 1999.
8. Miller KD, McCaskill-Stevens W, Sisk J et al: Combination Versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17: 3033-3037, 1999.
9. Sparano JA, O'Neill A, Schaefer PL et al: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 18: 2369-77, 2000.
10. National Cancer Institute of Canada Common Toxicity Criteria (NCIC CTC), version 2.0, March 23rd 1998. http://ctep.info.nih.gov/
11. Kaplan EL and Meyer P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-81, 1958.
12. Stemmler HJ, Gutschow K, Sommer H et al: Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Ann Oncol 12: 1393-1398, 2001.
13. Sancho JF, Enrech S, Menéndez P et al: Weekly docetaxel in combination with doxorubicin for advanced breast cancer. Ann Oncol 11(S4): 29, 2000 (abstract).
14. Hortobagyi GN: Can we cure limited metastatic breast cancer? J Clin Oncol 20: 620-623, 2002.
15. Nieto Y, Nawaz S, Jones RB et al: Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20: 707-718, 2002.
16. Nieto Y, Cagnoni PJ, Shpall EJ et al: Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 5: 1731-1737, 1999.
17. Blumenschein GR, Buzdar AU, Tashima CK et al: Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer. In: Salmon SE, Jones SE (eds): Adjuvant Therapy of Cancer. Amsterdam, The Netherlands, Elsevier North-Holland Publishing Co, 1977, pp 147-152.
18. Buzdar AU, Blumenschein GR, Smith TL et al: Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol 12: 27-40, 1979.
19. Kloke O, Klaassen U, Oberhoff C et al: Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. Breast Cancer Res Treat 55: 51-59, 1999.